Moderna Inc (MRNA : NASDAQ)
Common Stock
Follow MRNA
MRNA
Moderna Inc
WealthAwesomePerformance
1 Day
-6.75%
1 Week
+9.80%
1 Month
+11.48%
YTD
+712.80%
The Saturday TSX Wrap · free, every saturday morning. The week on the TSX, in five minutes.
Key Statistics
Market Cap
$101.49B
52W High
$280.80
52W Low
$22.28
P/E Ratio
-
50 Day MA
$194.47
200 Day MA
$92.57
Beta
1.17
Dividend Yield
-
Performance history
MRNA returns since 2018
Moderna Inc has returned +1.8% a year over the last 5 years, with 3 up years out of 7 full calendar years. Its deepest fall was −95.4% (Aug 2021 to Nov 2025).
1 year / yr
+913.0%
3 years / yr
+53.0%
5 years / yr
+1.8%
10 years / yr
—
Calendar-year returns
- 2018*−17.9%
- 2019+28.1%
- 2020+434.1%
- 2021+143.1%
- 2022−29.3%
- 2023−44.6%
- 2024−58.2%
- 2025−29.1%
- 2026*+750.6%
* Partial year (first year of data, or year to date).
$10,000 invested in MRNA
- 1 year ago$101,305
- 5 years ago$10,955
- 2018 (start of our data)$134,855
- Best year
- 2020: +434.1%
- Worst year
- 2024: −58.2%
- All-time high in our data
- $484 on Aug 9, 2021 · now −48.2%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Dec 2018 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past MRNA? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/10/2026 | $265.88 | $273.00 | $250.49 | $250.83 | $250.83 | 11,149,939 |
| 11/9/2026 | $257.86 | $280.80 | $253.33 | $269.00 | $269.00 | 12,357,425 |
| 11/6/2026 | $245.40 | $267.50 | $237.86 | $254.19 | $254.19 | 16,296,200 |
| 11/5/2026 | $258.01 | $261.00 | $237.65 | $241.46 | $241.46 | 12,032,003 |
| 11/4/2026 | $235.00 | $258.72 | $230.21 | $258.38 | $258.38 | 14,808,313 |
| 11/3/2026 | $222.01 | $235.50 | $220.23 | $228.44 | $228.44 | 9,515,743 |
| 11/2/2026 | $224.16 | $230.52 | $217.62 | $220.83 | $220.83 | 8,440,799 |
| 10/30/2026 | $220.53 | $227.81 | $217.22 | $221.72 | $221.72 | 8,999,800 |
| 10/29/2026 | $216.43 | $225.00 | $215.35 | $222.76 | $222.76 | 10,834,628 |
| 10/28/2026 | $204.00 | $218.16 | $202.62 | $214.16 | $214.16 | 12,038,620 |
Analyst Price Targets
Based on 23 analysts covering MRNA · as of Nov 10, 2026
Wall Street analysts forecast MRNA stock price to fall 38.4% over the next 12 months.
Consensus
Hold3.04 / 5.00
Avg. Target
US$154.47
-38.4% Upside
Previously US$145.42 on Nov 9, 2026
Current Price
US$250.83
Last close
Analyst Breakdown (23 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
104.6%
Annualized
90-Day Vol
197.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$299.87
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$266.21 | US$185.56 – US$381.91 |
| 60 trading days | US$282.54 | US$169.60 – US$470.69 |
| 90 trading days | US$299.87 | US$160.49 – US$560.28 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Financials
- Revenue (TTM)
- $2.52B
- EBITDA
- $-1.78B
- Profit Margin
- -110.46%
- ROE (TTM)
- -34.50%
- EPS (Diluted)
- -6.56
- Book Value
- 16.92
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Saturday TSX Wrap
The week on the TSX, in five minutes
- The biggest gainers and losers, and why they moved
- Sector and momentum moves at a glance
- The Canadian market stories you missed
Explore More
Common Questions About MRNA.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SMX | SMX (Security Matters) Public Limited Company Class A Ordinary Shares | $19.25 | +105.88% |
| PEPG | PepGen Ltd | $4.61 | +92.89% |
| TTEC | TTEC Holdings Inc | $2.40 | +72.04% |
| NNOX | Nano X Imaging Ltd | $0.37 | +59.80% |
| TANH | Tantech Holdings Ltd | $30.56 | +58.01% |
| AACG | ATA Creativity Global | $0.89 | +52.14% |
| ESLA | Estrella Immunopharma Inc. | $0.75 | +45.40% |
| MNDO | MIND CTI Ltd | $1.26 | +44.83% |
Latest MRNA news
Wire stories from the last 10 days. Links open the original publisher.
- What Invesco S&P 500 Equal Weight ETF (RSP) Bought: Moderna Leads on Nov. 6
Yahoo Finance · 1d ago
- Moderna (MRNA) Stock Fair Value Rises After Intismeran Data And Q3 Beat
Yahoo Finance · 2d ago
- MRNA support and resistance levels to watch
Yahoo Finance · 2d ago